An apolipoprotein B100 mimotope prevents obesity in mice

Hyo Joon Kim, Hee Jong Lee, Jung Soon Choi, Jemin Han, Ji Young Kim, Hyun Kyun Na, Hae Jung Joung, Young Sik Kim, Bert Binas

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Although apolipoprotein B100 (ApoB100) plays a key role in peripheral fat deposition, it is not considered a suitable therapeutic target in obesity. In the present study we describe a novel ApoB100 mimotope, peptide pB1, and the use of pB1-based vaccine-like formulations (BVFs) against high-fat diet (HFD)-induced obesity. In HFD- compared with chow-fed adolescent mice, BVFs reduced the 3-month body-weight gains attributable to increased dietary fat by 44-65 %, and prevented mesenteric fat accumulation and liver steatosis. The body-weight reductions paralleled the titres of pB1-reactive immunoglobulin G (IgG) antibodies, and pB1-reactive antibodies specifically recognized native ApoB100 and a synthetic peptide from the C-terminal half of ApoB100. In cultured 3T3L1 adipocytes, anti-pB1 antibodies increased lipolysis and inhibited low-density lipoprotein (LDL) uptake. In cultured RAW 264.7 macrophages, the same antibodies enhanced LDL uptake (without causing foam cell formation). These findings make ApoB100 a promising target for an immunization strategy against HFD-induced obesity.

Original languageEnglish
Pages (from-to)105-116
Number of pages12
JournalClinical Science
Volume130
Issue number2
DOIs
Publication statusPublished - 2016

Fingerprint

Apolipoproteins
Obesity
High Fat Diet
LDL Lipoproteins
Antibodies
Vaccines
Fats
Body Weight
Foam Cells
Lipolysis
Dietary Fats
Fatty Liver
Adipocytes
Weight Gain
Weight Loss
Anti-Idiotypic Antibodies
Immunization
Immunoglobulin G
Macrophages

Keywords

  • ApoB100
  • High-fat-diet-induced obesity
  • Humoral immunity
  • Mimotope

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kim, H. J., Lee, H. J., Choi, J. S., Han, J., Kim, J. Y., Na, H. K., ... Binas, B. (2016). An apolipoprotein B100 mimotope prevents obesity in mice. Clinical Science, 130(2), 105-116. https://doi.org/10.1042/CS20150423

An apolipoprotein B100 mimotope prevents obesity in mice. / Kim, Hyo Joon; Lee, Hee Jong; Choi, Jung Soon; Han, Jemin; Kim, Ji Young; Na, Hyun Kyun; Joung, Hae Jung; Kim, Young Sik; Binas, Bert.

In: Clinical Science, Vol. 130, No. 2, 2016, p. 105-116.

Research output: Contribution to journalArticle

Kim, HJ, Lee, HJ, Choi, JS, Han, J, Kim, JY, Na, HK, Joung, HJ, Kim, YS & Binas, B 2016, 'An apolipoprotein B100 mimotope prevents obesity in mice', Clinical Science, vol. 130, no. 2, pp. 105-116. https://doi.org/10.1042/CS20150423
Kim HJ, Lee HJ, Choi JS, Han J, Kim JY, Na HK et al. An apolipoprotein B100 mimotope prevents obesity in mice. Clinical Science. 2016;130(2):105-116. https://doi.org/10.1042/CS20150423
Kim, Hyo Joon ; Lee, Hee Jong ; Choi, Jung Soon ; Han, Jemin ; Kim, Ji Young ; Na, Hyun Kyun ; Joung, Hae Jung ; Kim, Young Sik ; Binas, Bert. / An apolipoprotein B100 mimotope prevents obesity in mice. In: Clinical Science. 2016 ; Vol. 130, No. 2. pp. 105-116.
@article{ed080fd6b5ec4390b2fe7a68b9c84900,
title = "An apolipoprotein B100 mimotope prevents obesity in mice",
abstract = "Although apolipoprotein B100 (ApoB100) plays a key role in peripheral fat deposition, it is not considered a suitable therapeutic target in obesity. In the present study we describe a novel ApoB100 mimotope, peptide pB1, and the use of pB1-based vaccine-like formulations (BVFs) against high-fat diet (HFD)-induced obesity. In HFD- compared with chow-fed adolescent mice, BVFs reduced the 3-month body-weight gains attributable to increased dietary fat by 44-65 {\%}, and prevented mesenteric fat accumulation and liver steatosis. The body-weight reductions paralleled the titres of pB1-reactive immunoglobulin G (IgG) antibodies, and pB1-reactive antibodies specifically recognized native ApoB100 and a synthetic peptide from the C-terminal half of ApoB100. In cultured 3T3L1 adipocytes, anti-pB1 antibodies increased lipolysis and inhibited low-density lipoprotein (LDL) uptake. In cultured RAW 264.7 macrophages, the same antibodies enhanced LDL uptake (without causing foam cell formation). These findings make ApoB100 a promising target for an immunization strategy against HFD-induced obesity.",
keywords = "ApoB100, High-fat-diet-induced obesity, Humoral immunity, Mimotope",
author = "Kim, {Hyo Joon} and Lee, {Hee Jong} and Choi, {Jung Soon} and Jemin Han and Kim, {Ji Young} and Na, {Hyun Kyun} and Joung, {Hae Jung} and Kim, {Young Sik} and Bert Binas",
year = "2016",
doi = "10.1042/CS20150423",
language = "English",
volume = "130",
pages = "105--116",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "2",

}

TY - JOUR

T1 - An apolipoprotein B100 mimotope prevents obesity in mice

AU - Kim, Hyo Joon

AU - Lee, Hee Jong

AU - Choi, Jung Soon

AU - Han, Jemin

AU - Kim, Ji Young

AU - Na, Hyun Kyun

AU - Joung, Hae Jung

AU - Kim, Young Sik

AU - Binas, Bert

PY - 2016

Y1 - 2016

N2 - Although apolipoprotein B100 (ApoB100) plays a key role in peripheral fat deposition, it is not considered a suitable therapeutic target in obesity. In the present study we describe a novel ApoB100 mimotope, peptide pB1, and the use of pB1-based vaccine-like formulations (BVFs) against high-fat diet (HFD)-induced obesity. In HFD- compared with chow-fed adolescent mice, BVFs reduced the 3-month body-weight gains attributable to increased dietary fat by 44-65 %, and prevented mesenteric fat accumulation and liver steatosis. The body-weight reductions paralleled the titres of pB1-reactive immunoglobulin G (IgG) antibodies, and pB1-reactive antibodies specifically recognized native ApoB100 and a synthetic peptide from the C-terminal half of ApoB100. In cultured 3T3L1 adipocytes, anti-pB1 antibodies increased lipolysis and inhibited low-density lipoprotein (LDL) uptake. In cultured RAW 264.7 macrophages, the same antibodies enhanced LDL uptake (without causing foam cell formation). These findings make ApoB100 a promising target for an immunization strategy against HFD-induced obesity.

AB - Although apolipoprotein B100 (ApoB100) plays a key role in peripheral fat deposition, it is not considered a suitable therapeutic target in obesity. In the present study we describe a novel ApoB100 mimotope, peptide pB1, and the use of pB1-based vaccine-like formulations (BVFs) against high-fat diet (HFD)-induced obesity. In HFD- compared with chow-fed adolescent mice, BVFs reduced the 3-month body-weight gains attributable to increased dietary fat by 44-65 %, and prevented mesenteric fat accumulation and liver steatosis. The body-weight reductions paralleled the titres of pB1-reactive immunoglobulin G (IgG) antibodies, and pB1-reactive antibodies specifically recognized native ApoB100 and a synthetic peptide from the C-terminal half of ApoB100. In cultured 3T3L1 adipocytes, anti-pB1 antibodies increased lipolysis and inhibited low-density lipoprotein (LDL) uptake. In cultured RAW 264.7 macrophages, the same antibodies enhanced LDL uptake (without causing foam cell formation). These findings make ApoB100 a promising target for an immunization strategy against HFD-induced obesity.

KW - ApoB100

KW - High-fat-diet-induced obesity

KW - Humoral immunity

KW - Mimotope

UR - http://www.scopus.com/inward/record.url?scp=84952042839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952042839&partnerID=8YFLogxK

U2 - 10.1042/CS20150423

DO - 10.1042/CS20150423

M3 - Article

VL - 130

SP - 105

EP - 116

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 2

ER -